The observation that antibody checkpoints determine clinical efficacy of ipilimumab was not unexpected, since anti-CTLA-4 antibody therapy in the mouse critically depends on FcγR-mediated deletion of regulatory T cells (77–80), which express CTLA-4 at higher levels compared with effector T cells in the tumor microenvironment (76). Here, CTLA4 is linked to neoplasm.